论文部分内容阅读
目的分析甘精胰岛素对新诊断2型糖尿病患者血糖波动的作用,探讨其临床适用性。方法选择68例新诊断2型糖尿病患者,随机分为实验组和对照组各34例,对照组采用精蛋白重组人胰岛素混合注射液治疗,实验组采用甘精胰岛素作为治疗药物。结果两组患者治疗前的血糖指标比较,血糖控制正常后患者空腹血糖、三餐后2h血糖指标的均值、标准差较对照组患者的明显降低。在治疗过程中,实验组低血糖发生率17.6%,而对照组低血糖发生率41.1%,实验组低血糖发生率明显低于对照组。结论甘精胰岛素对降低新诊断2型糖尿病患者血糖有明显的效果,且血糖达标后波动小,低血糖发生率低,适合临床长期推广应用。
Objective To analyze the effect of insulin glargine on blood glucose fluctuation in newly diagnosed type 2 diabetic patients and explore its clinical applicability. Methods Sixty-eight patients newly diagnosed with type 2 diabetes mellitus were randomly divided into experimental group and control group (n = 34). The control group was treated with protamine recombinant human insulin injections. Glargine was used as the therapeutic drug in the experimental group. Results Before treatment, the fasting blood glucose, the mean and standard deviation of blood glucose at 2h after meals were significantly lower than those in the control group after treatment. In the course of treatment, the incidence of hypoglycemia in the experimental group was 17.6%, while that in the control group was 41.1%. The incidence of hypoglycemia in the experimental group was significantly lower than that in the control group. Conclusion Glargine has a significant effect on reducing the blood sugar of newly diagnosed type 2 diabetic patients, and its blood glucose has little fluctuation and low incidence of hypoglycemia after it reaches the standard of blood glucose. It is suitable for long-term clinical application.